- Home
- MYGN vs CRGY Comparison
MYGN vs CRGY Comparison
Compare MYGN & CRGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CRGY
- Stock Information
- Founded
- MYGN 1991
- CRGY 1986
- Country
- MYGN United States
- CRGY United States
- Employees
- MYGN N/A
- CRGY N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRGY Oil & Gas Production
- Sector
- MYGN Health Care
- CRGY Energy
- Exchange
- MYGN Nasdaq
- CRGY Nasdaq
- Market Cap
- MYGN 2.0B
- CRGY 2.0B
- IPO Year
- MYGN 1995
- CRGY N/A
- Fundamental
- Price
- MYGN $13.50
- CRGY $14.88
- Analyst Decision
- MYGN Hold
- CRGY Buy
- Analyst Count
- MYGN 11
- CRGY 12
- Target Price
- MYGN $24.27
- CRGY $16.80
- AVG Volume (30 Days)
- MYGN 1.1M
- CRGY 5.0M
- Earning Date
- MYGN 02-25-2025
- CRGY 03-03-2025
- Dividend Yield
- MYGN N/A
- CRGY 3.24%
- EPS Growth
- MYGN N/A
- CRGY 42.32
- EPS
- MYGN N/A
- CRGY 0.53
- Revenue
- MYGN $823,600,000.00
- CRGY $2,713,358,000.00
- Revenue This Year
- MYGN $13.82
- CRGY $25.74
- Revenue Next Year
- MYGN $4.59
- CRGY $26.23
- P/E Ratio
- MYGN N/A
- CRGY $28.02
- Revenue Growth
- MYGN 12.15
- CRGY 12.60
- 52 Week Low
- MYGN $12.87
- CRGY $9.88
- 52 Week High
- MYGN $29.30
- CRGY $15.54
- Technical
- Relative Strength Index (RSI)
- MYGN 32.61
- CRGY 61.02
- Support Level
- MYGN $13.04
- CRGY $12.90
- Resistance Level
- MYGN $13.77
- CRGY $13.90
- Average True Range (ATR)
- MYGN 0.60
- CRGY 0.45
- MACD
- MYGN 0.14
- CRGY 0.05
- Stochastic Oscillator
- MYGN 24.51
- CRGY 94.50
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.